Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Small Cell Lung Carcinoma 13Lung Neoplasms 13Colorectal Neoplasms 6Sarcoma 5Neoplasm Metastasis 5Melanoma 5Adenocarcinoma of Lung 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3NSCLC 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Mesothelioma 2Extensive Stage Small Cell Lung Cancer 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uveal Melanoma 1Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Germ Cell Tumor 1Small Cell Lung Cancer Extensive Stage 1SCLC, Extensive Stage 1Radiation Pneumonitis 1Perioperative Immunotherapy 1Pancreatic Neoplasms 1Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non Squamous Non-small Cell Lung Cancer 1

Interventions

dabrafenib 2Trastuzumab 2zimberelimab 1vandetanib 1trametinib 1tislelizumab 1tipifarnib 1surufatinib 1spartalizumab 1sargramostim 1cobimetinib 1aldesleukin 1Vemurafenib 1Tamoxifen 1Radiotherapy 1PLX8394 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × tislelizumab × Thoracic × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡